Introducing an Improved ctDNA Tumor Fraction Method to Add Value in Translational Research, Clinical Trials & CDx Development
Time: 8:30 am
day: Day One
Details:
• Discussion on the value of ctDNA monitoring for research and clinical trial programs, including both early- and late-stage disease for MRD and treatment response
• Confidence in negative results from a liquid biopsy test, now possible for wild-type biomarkers in trial enrolment
• New data on the value of ctDNA tumor fraction in lung, breast, bladder, and kidney cancers
